Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Aug;52(8):1194-1198.
doi: 10.1038/bmt.2017.91. Epub 2017 May 15.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

S Huhn  1 , N Weinhold  1   2 , J Nickel  1 , M Pritsch  1 , T Hielscher  3 , M Hummel  3 , U Bertsch  1   4 , B Huegle-Doerr  1 , M Vogel  5 , R Angermund  5 , M Hänel  6 , H J Salwender  7 , K Weisel  8 , J Dürig  9 , M Görner  10 , H Kirchner  11 , N Peter  12 , U Graeven  13 , F Lordick  14   15 , M Hoffmann  16 , P Reimer  17 , I W Blau  18 , A Jauch  19 , K Dembowsky  20 , T Möhler  1   21 , P Wuchter  1   22 , H Goldschmidt  1   4
Affiliations
Clinical Trial

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

S Huhn et al. Bone Marrow Transplant. 2017 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

SH, NW, JN, MP, TH, MHu, UB, BH-D, MHä, JD, MG, HK, UG, MHo, PR, AJ, NP and KD declare no conflict of interest. MV and RA are employees of Janssen and hold stock in Johnson & Johnson; HJS—Celgene: honoraria, travel grants and Amgen: honoraria; KW—Honoraria and Advisory Board von Amgen, BMS, Celgene, Janssen, Novartis, Takeda; FL—advisory role: BioNTech, Bristol-Myers-Squibb, Eli Lilly, GANYMED Pharmaceuticals, Merck Sharp & Dohme, Roche Pharma AG. Lecture honoraria: Amgen, Astra Zeneca, Eli Lilly, Merck Sharp & Dohme, Roche Pharma AG, Servier. Research grant: Boehringer Ingelheim, Fresenius Biotech. Travel grants: Amgen, Bayer, Merck Sharp & Dohme, Roche Pharma AG, Taiho Pharmaceutical; IWB—scientific grants Jabssen-Cilag and Celgene. TM is an employee of inVentiv Health; PW—Honoraria and membership on Advisory Boards of Sanofi-Aventis. Membership on Advisory Boards and Travel Grants from Hexal AG; HG—research support (institutions): Celgene, Janssen, Chugai, Novartis, BMS; Advisory Boards (institutions): Janssen, Celgene, Novartis, Amgen Takeda, BMS; Honoraria: Celgene, Janssen, Novartis, Chugai, BMS.

Figures

Figure 1
Figure 1
(a) GMMG-MM5—correlation between tumor load in PB and therapy cycle; N=106. (b) GMMG-MM5—correlation between tumor load in PB and response to therapy. (c) GMMG-MM5 and GMMG-HD4—tumor load in PB at diagnosis and after different Bortezomib-based induction therapy regimes. PAd=bortezomib/doxorubicin/reduced dose dexamethasone (240 mL per cycle); VCD=bortezomib/cyclophosphamide/dexamethasone; PAD=bortezomib/doxorubicin/dexamethasone (480 mg per cycle). (d) GMMG-MM5—tumor load in BM and PB at the time point at which the patients had reached CR (after IT, after ASCT and after Cons.). (e) GMMG-MM5—correlation between tumor load in PB and therapy cycle, stratified for the presence or absence of high-risk cytogenetics (HR=amp(1q) more than three copies, deletion 17p13, t(4:14) and t(14:16); SR=low risk (all others)); HR=1; SR=0. (f) GMMG-MM5—correlation between tumor load in PB and therapy cycle, stratified for ISS Stage. Ordinary boxplots ignoring censoring. (g) GMMG-MM5—correlation between tumor load in BM and PB if PB is positive; N=14 pairs. (h) Tumor load in BM and PB if PB is positive; N=14 pairs.
Figure 1
Figure 1
(a) GMMG-MM5—correlation between tumor load in PB and therapy cycle; N=106. (b) GMMG-MM5—correlation between tumor load in PB and response to therapy. (c) GMMG-MM5 and GMMG-HD4—tumor load in PB at diagnosis and after different Bortezomib-based induction therapy regimes. PAd=bortezomib/doxorubicin/reduced dose dexamethasone (240 mL per cycle); VCD=bortezomib/cyclophosphamide/dexamethasone; PAD=bortezomib/doxorubicin/dexamethasone (480 mg per cycle). (d) GMMG-MM5—tumor load in BM and PB at the time point at which the patients had reached CR (after IT, after ASCT and after Cons.). (e) GMMG-MM5—correlation between tumor load in PB and therapy cycle, stratified for the presence or absence of high-risk cytogenetics (HR=amp(1q) more than three copies, deletion 17p13, t(4:14) and t(14:16); SR=low risk (all others)); HR=1; SR=0. (f) GMMG-MM5—correlation between tumor load in PB and therapy cycle, stratified for ISS Stage. Ordinary boxplots ignoring censoring. (g) GMMG-MM5—correlation between tumor load in BM and PB if PB is positive; N=14 pairs. (h) Tumor load in BM and PB if PB is positive; N=14 pairs.
See this image and copyright information in PMC

References

    1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128. - PMC - PubMed
    1. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328–e346. - PubMed
    1. Avet-Loiseau H, Corre J, Lauwers-Cances V, Chretien M-L, Robillard N, Leleu X et al. Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 Trial. Blood 2015; 126: 191.
    1. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540–2547. - PubMed
    1. Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF. Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2016; 51: 2–12. - PubMed

Publication types

Substances